News

The ProAir Digihaler, a digital inhaler designed for people with asthma and chronic obstructive pulmonary disease (COPD) to monitor their inhaler usage through the use of a mobile app, is now available by prescription in the U.S. The albuterol inhaler (albuterol sulfate, 117 micrograms), developed by Teva…

Chronic obstructive pulmonary disease (COPD) appears to be a risk factor for lung cancer, liver cancer, and colorectal cancer, regardless of smoking status, a data study from Korea reported. The study, “Cancer development in patients with COPD: a retrospective analysis of the National Health Insurance Service-National…

Breztri Aerosphere, AstraZeneca’s triple combination therapy for chronic obstructive pulmonary disease (COPD), significantly reduces the frequency of moderate or severe exacerbations, compared to dual combination therapies, in patients with moderate to very severe forms of the disease, a Phase 3 trial shows. The findings were presented…

A vitamin D deficiency in people with chronic obstructive pulmonary disease (COPD) is associated with a decline in lung function, and with increased odds of acute exacerbations, a large-scale analysis found.  These results identify vitamin D as a potential biomarker…

Starting a pulmonary rehabilitation program within three months of hospitalization for chronic obstructive pulmonary disease, or COPD, improved the rate of survival over one year by 6.7%, according to new research. The study, “Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year…

Having small airways compared to lung size may contribute to the development of chronic obstructive pulmonary disease (COPD) in many non-smokers, a retrospective study has found. The finding broadens understanding of the risk factors involved in COPD, say  Columbia University Irving Medical Center researchers, whose work, “Association of Dysanapsis…

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…

Following a stop due to the COVID-19 pandemic, the Medical University of South Carolina (MUSC) has become the first medical center to restart the AIRFLOW-3 clinical trial, which is testing a procedure called targeted lung denervation as a potential therapy for chronic obstructive pulmonary disease (COPD). “We’re…

As air pollution levels fall in the wake of widespread lockdowns due to the COVID-19 pandemic, one in six U.K. residents with lung conditions report improving symptoms. More than half report a noticeable decrease in air pollution since lockdowns began. These figures come from a British Lung Foundation…

Remestemcel-L, Mesoblast’s lead candidate stem cell therapy for inflammatory diseases, improves lung function and exercise capacity in people with chronic obstructive pulmonary disease (COPD) and a high degree of inflammation, data from a post-hoc analysis of a Phase 2 trial show. Findings were presented in an…